ストックスクリーナーアプリを入手
1.61
11.81%
0.17
アフターアワーズ：
1.58
-0.03
-1.86%
前日終値:
$1.44
開ける：
$1.44
24時間の取引高:
2.31M
Relative Volume:
1.13
時価総額：
$96.49M
収益：
-
当期純損益:
$-40.33M
株価収益率:
-0.8994
EPS:
-1.79
ネットキャッシュフロー:
$-39.53M
1週間 パフォーマンス:
-0.62%
1か月 パフォーマンス:
-53.74%
6か月 パフォーマンス:
-47.21%
1年 パフォーマンス:
-59.85%
1日の値動き範囲:
$1.385
$1.635
1週間の範囲:
$1.35
$1.71
52週間の値動き範囲:
$1.35
$5.08
Eledon Pharmaceuticals Inc Stock (ELDN) Company Profile
名前
Eledon Pharmaceuticals Inc
セクター
電話
949-238-8090
住所
19800 MACARTHUR BLVD., IRVINE
ELDN を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ELDN
Eledon Pharmaceuticals Inc
|
1.61 | 108.05M | 0 | -40.33M | -39.53M | -1.79 |
|
VRTX
Vertex Pharmaceuticals Inc
|
424.00 | 108.28B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
761.45 | 79.44B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
434.23 | 57.65B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
906.74 | 56.58B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
206.93 | 42.39B | 447.02M | -1.18B | -906.14M | -6.1812 |
Eledon Pharmaceuticals Inc Stock (ELDN) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-06-18 | 再開されました | H.C. Wainwright | Buy |
| 2025-01-28 | 開始されました | Guggenheim | Buy |
| 2022-05-13 | 再開されました | Cantor Fitzgerald | Overweight |
| 2021-03-23 | 開始されました | Cantor Fitzgerald | Overweight |
Eledon Pharmaceuticals Inc (ELDN) 最新ニュース
Eledon Shares Fall Nearly 50% After Phase 2 Results - Orange County Business Journal
What drives Eledon Pharmaceuticals Inc stock priceSwing Trading Ideas & Small Entry Cost Trading - earlytimes.in
Midday Stock Roundup: RxSight up 14% - Orange County Business Journal
How analysts rate Eledon Pharmaceuticals Inc. stock todayWeekly Risk Summary & Growth Focused Stock Pick Reports - newser.com
Will Eledon Pharmaceuticals Inc. (2TK) stock test record highs in 20252025 Risk Factors & Long-Term Growth Portfolio Plans - newser.com
Is Eledon Pharmaceuticals Inc. (2TK) stock supported by strong fundamentalsJuly 2025 Closing Moves & High Return Stock Watch Alerts - newser.com
Eledon Pharmaceuticals Reports Q3 2025 Financial Results - TipRanks
How analysts revise price targets for Eledon Pharmaceuticals Inc. (2TK) stockWeekly Trade Report & AI Forecasted Entry and Exit Points - newser.com
What technical patterns form on Eledon Pharmaceuticals Inc. (2TK) stock chartsWeekly Gains Report & Accurate Entry/Exit Alerts - newser.com
Is Eledon Pharmaceuticals Inc. (2TK) stock worth buying before Fed actionTrend Reversal & Free Safe Capital Growth Stock Tips - newser.com
Eledon Pharmaceuticals Inc. stock momentum explainedEarnings Beat & Free Community Consensus Stock Picks - newser.com
Why Eledon Pharmaceuticals Inc. (2TK) stock could be top winnerEarnings Trend Report & Long-Term Growth Portfolio Plans - newser.com
Can Eledon Pharmaceuticals Inc. (2TK) stock sustain margin levelsJuly 2025 EndofMonth & Capital Protection Trading Alerts - newser.com
Eledon’s transplant rejection drug shows promise in Phase I/II diabetes trial - Clinical Trials Arena
Visual trend scoring systems applied to Eledon Pharmaceuticals Inc.Weekly Profit Recap & AI Driven Price Forecasts - newser.com
Market reaction to Eledon Pharmaceuticals Inc.’s recent newsTrade Signal Summary & Safe Capital Investment Plans - newser.com
Why Eledon Pharmaceuticals Inc. (2TK) stock stays on buy lists2025 Price Action Summary & Breakout Confirmation Alerts - newser.com
Eledon Pharmaceuticals stock rises after positive islet transplant data By Investing.com - Investing.com Australia
Eledon Pharmaceuticals stock rises after positive islet transplant data - Investing.com
Eledon’s anti-CD40L antibody shows promise in diabetes trial - Investing.com
Eledon reports preliminary data from first six patients with type 1 diabetes treated with tegoprubart as the core immunosuppressant - MarketScreener
Eledon Pharmaceuticals (ELDN) Reports Promising Trial Results fo - GuruFocus
Eledon Pharmaceuticals Reports Encouraging Preliminary Results for Tegoprubart in Islet Transplantation for Type 1 Diabetes - Quiver Quantitative
Eledon’s anti-CD40L antibody shows promise in diabetes trial By Investing.com - Investing.com Nigeria
Eledon (NASDAQ: ELDN) tegoprubart study: 6 T1D islet transplant patients insulin-free - Stock Titan
Guggenheim Lowers Price Target for ELDN While Maintaining Buy Ra - GuruFocus
Is Eledon Pharmaceuticals Inc. stock a buy in volatile marketsJuly 2025 Decliners & AI Optimized Trading Strategy Guides - newser.com
Transcript : Eledon Pharmaceuticals, Inc. Presents at Guggenheim Securities 2nd Annual Healthcare Innovation Conference, Nov-12-2025 10 - MarketScreener
Eledon Pharmaceuticals Inc (ELDN) 財務データ
収益
当期純利益
現金流量
EPS
2.13%
4.32%
大文字化:
|
ボリューム (24 時間):